Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume 96, Issue 1 , Pages 85-90 , January 2002

An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: development of a model for estimating recurrent direct costs

  • J.J. Wilkins

      Affiliations

    • Division of Pharmacology, Faculty of Health Sciences, University of Cape Town, South Africa
    • Corresponding Author InformationAddress for correspondence: Justin Wilkins, Division of Pharmacology, K45 Old Main Building, Groote Schuur Hospital, Observatory 7925, South Africa; phone +27 (0)21 406-6659, fax + 27 (0)21 448 1989.
    • ,
  • P.I. Folb

      Affiliations

    • Division of Pharmacology, Faculty of Health Sciences, University of Cape Town, South Africa
    • ,
  • N. Valentine

      Affiliations

    • Health Economics Unit, Faculty of Health Sciences, University of Cape Town, South Africa
    • ,
  • K.I. Barnes

      Affiliations

    • Division of Pharmacology, Faculty of Health Sciences, University of Cape Town, South Africa

Received 2 October 2000 ,Revised 5 June 2001 ,Accepted 19 June 2001.

References 

  1. Bac DJ, Cox GA, Isaacson M. In vivo and in vitro chloroquine-resistant malaria in South Africa. South African Medical Journal. 1985;67:937–938
  2. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics. 1994;3:95–104
  3. Coyle D. Statistical analysis in pharmacoeconomic studies: a review of current issues and standards. PharmacoEconomics. 1996;9:506–516
  4. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making. 1985;5:157–177
  5. Drummond MF, Menzin J, Oster G. Methodological issues in economic assessments of new therapies: the case of colony-stimulating factors. PharmacoEconomics. 1994;6:18–26
  6. Dürrheim DN, la Grange JJP, Govere J, Mngomezulu NM. Accuracy of a rapid immunochromatographic card test for Plasmodium falciparum in a malaria control programme in South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1998;92:32–33
  7. Fogh B, Jepson S, Effersoe P. Chloroquine resistance in Plasmodium falciparum in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1979;73:228–229
  8. Goodman CA, Coleman PG, Mills AJ. Costeffectiveness of malaria control in sub-Saharan Africa. Lancet. 1999;354:378–385
  9. Goodman CA, Coleman PG, Mills AJ. In: Economic Analysis of Malaria Control in Sub-Saharan Africa. Geneva: Global Forum for Health Research; 2000;p. 159–182
  10. Govere JM, la Grange JJ, Dürrheim DN, Freese JA, Sharp BL, Mabuza A, et al. Sulfadoxine-pyrimethamine effectiveness against Plasmodium falciparum malaria in Mpumalanga Province, South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999;93:644
  11. Govere JM, Dürrheim DN, la Grange JJ, Mabuza A, Booman M. Community knowledge and perceptions about malaria and practices influencing malaria control in Mpumalanga Province, South Africa. South African Medical Journal. 2000;90:611–616
  12. Murray CJL. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bulletin of the World Health Organization. 1994;72:429–445
  13. Murray CJL, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bulletin of the World Health Organization. 1994;72:495–509
  14. Sharp BL, le Sueur D. Malaria in South Africa— the past, the present and selected implications for the future. South African Medical Journal. 1996;86:83–89
  15. Tester-Dalderup CBM. Antiprotozoal drugs. In: 13th edn.  Dukes MNG editors. Meyler's Side Effects of Drugs: an Encyclopedia of Adverse Reactions and Interactions. Amsterdam: Elsevier; 1996;p. 799–822
  16. Velásquez G, Boulet P. In: Globalization and Access to Drugs: Implications of the WTO/TRIPS Agreement. Geneva: WHO Action Programme on Essential Drugs; 1997;

PII: S0035-9203(02)90251-8

Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume 96, Issue 1 , Pages 85-90 , January 2002

Article Tools